Alternative Data for Lexicon Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 99 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 4 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,038 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 195 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 13,645 | Sign up | Sign up | Sign up |
| X Followers | 655 | Sign up | Sign up | Sign up |
| X Mentions | 19 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 23 | Sign up | Sign up | Sign up |
| Linkedin Employees | 283 | Sign up | Sign up | Sign up |
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
| Price | $1.72 |
| Target Price | Sign up |
| Volume | 3,642,071 |
| Market Cap | $703M |
| Year Range | $0.87 - $1.76 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting With Fine Tuned Targets And TrialsFebruary 22 - Yahoo |
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th AnniversaryJanuary 23 - GlobeNewswire |
|
 |
Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go ForwardJanuary 21 - SeekingAlpha |
 |
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 15 - SeekingAlpha |
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”January 9 - GlobeNewswire |
|
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceJanuary 7 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 14M | 10,000 | 14M | -13M | -10M | -0.040 |
| Q2 '25 | 29M | 210,000 | 29M | 3.3M | 5.7M | 0.010 |
| Q1 '25 | 1.3M | 30,000 | 1.2M | -25M | -23M | -0.070 |
| Q4 '24 | 27M | 350,000 | 26M | -34M | -30M | -0.090 |
| Q3 '24 | 1.8M | 71,000 | 1.7M | -65M | -60M | -0.180 |
Insider Transactions View All
| DEBBANE RAYMOND filed to buy 1,906,186 shares at $1.5. February 27 '26 |
| DEBBANE RAYMOND filed to buy 1,904,186 shares at $1.5. February 25 '26 |
| DEBBANE RAYMOND filed to buy 1,804,186 shares at $1.5. February 23 '26 |
| DEBBANE RAYMOND filed to buy 1,704,186 shares at $1.4. February 23 '26 |
| DEBBANE RAYMOND filed to buy 1,654,186 shares at $1.3. February 18 '26 |
Similar companies
Read more about Lexicon Pharmaceuticals (LXRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Lexicon Pharmaceuticals
The Market Cap of Lexicon Pharmaceuticals is $703M.
Currently, the price of one share of Lexicon Pharmaceuticals stock is $1.72.
The LXRX stock price chart above provides a comprehensive visual representation of Lexicon Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Lexicon Pharmaceuticals shares. Our platform offers an up-to-date LXRX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Lexicon Pharmaceuticals (LXRX) does not offer dividends to its shareholders. Investors interested in Lexicon Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Lexicon Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
